Coastline Trust Co Cuts Stock Position in Merck & Co., Inc. (NYSE:MRK)

Coastline Trust Co cut its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 6.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 37,389 shares of the company’s stock after selling 2,577 shares during the quarter. Coastline Trust Co’s holdings in Merck & Co., Inc. were worth $4,076,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Constitution Capital LLC boosted its stake in Merck & Co., Inc. by 5.9% during the fourth quarter. Constitution Capital LLC now owns 3,600 shares of the company’s stock worth $392,000 after buying an additional 200 shares during the period. Richard P Slaughter Associates Inc boosted its stake in Merck & Co., Inc. by 8.8% during the third quarter. Richard P Slaughter Associates Inc now owns 13,532 shares of the company’s stock worth $1,393,000 after buying an additional 1,091 shares during the period. Wealthspire Advisors LLC boosted its stake in shares of Merck & Co., Inc. by 37.0% during the third quarter. Wealthspire Advisors LLC now owns 57,526 shares of the company’s stock valued at $5,922,000 after purchasing an additional 15,529 shares during the period. Valued Wealth Advisors LLC purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at $42,000. Finally, AustralianSuper Pty Ltd purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at $15,818,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Price Performance

Shares of MRK stock traded down $0.64 during trading hours on Tuesday, hitting $130.35. 6,550,741 shares of the company’s stock were exchanged, compared to its average volume of 8,717,681. The company has a quick ratio of 1.00, a current ratio of 1.25 and a debt-to-equity ratio of 0.89. The firm has a market cap of $330.13 billion, a P/E ratio of 935.21, a P/E/G ratio of 0.52 and a beta of 0.38. The firm has a 50 day moving average of $125.24 and a two-hundred day moving average of $113.04. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its earnings results on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.12. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The business had revenue of $14.63 billion during the quarter, compared to the consensus estimate of $14.49 billion. During the same period in the prior year, the company posted $1.62 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Sell-side analysts forecast that Merck & Co., Inc. will post 8.59 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 5th. Investors of record on Friday, March 15th will be paid a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 2.36%. The ex-dividend date of this dividend is Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio is currently 2,200.00%.

Analyst Ratings Changes

MRK has been the subject of a number of recent analyst reports. Truist Financial reissued a “buy” rating and set a $142.00 target price (up from $139.00) on shares of Merck & Co., Inc. in a research note on Thursday, March 28th. StockNews.com upgraded Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. Wells Fargo & Company lifted their price objective on Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a report on Wednesday, March 27th. TheStreet downgraded shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a report on Monday, March 4th. Finally, Barclays boosted their target price on shares of Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $129.71.

Get Our Latest Analysis on MRK

Insider Activity at Merck & Co., Inc.

In related news, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total value of $124,890.00. Following the completion of the transaction, the insider now directly owns 19,569 shares of the company’s stock, valued at approximately $2,443,972.41. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Merck & Co., Inc. news, EVP Steven Mizell sold 50,694 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the completion of the sale, the executive vice president now owns 23,619 shares in the company, valued at $2,991,346.35. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Joseph Romanelli sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total value of $124,890.00. Following the sale, the insider now owns 19,569 shares of the company’s stock, valued at approximately $2,443,972.41. The disclosure for this sale can be found here. 0.20% of the stock is owned by corporate insiders.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.